RBC Europe’s Core Laboratories CLB Stock Holding History

RBC Europe’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,481	Closed	-$346K	–	722
2021 Q3	$346K	Hold	12,481	–	–	0.01%	232
2021 Q2	$486K	Buy	12,481 +7,761	+164%	+$278K	0.02%	207
2021 Q1	$136K	Buy	4,720 +1,000	+27%	+$34.2K	0.01%	349
2020 Q4	$98.6K	Hold	3,720	–	–	0.01%	390
2020 Q3	$56.8K	Hold	3,720	–	–	﹤0.01%	438
2020 Q2	$75.6K	Buy	3,720 +1,164	+46%	+$20.9K	0.01%	367
2020 Q1	$26.4K	Hold	2,556	–	–	﹤0.01%	502
2019 Q4	$96.3K	Hold	2,556	–	–	0.01%	349
2019 Q3	$119K	Hold	2,556	–	–	0.01%	303
2019 Q2	$134K	Buy	2,556 +1,456	+132%	+$85.4K	0.01%	301
2019 Q1	$75.8K	Hold	1,100	–	–	0.01%	381
2018 Q4	$65.6K	Hold	1,100	–	–	0.01%	387
2018 Q3	$127K	Hold	1,100	–	–	0.01%	315
2018 Q2	$139K	Buy	1,100 +694	+171%	+$84.5K	0.02%	300
2018 Q1	$43.9K	Hold	406	–	–	0.01%	487
2017 Q4	$44.5K	Hold	406	–	–	0.01%	491
2017 Q3	$40.1K	Buy	+406	New	+$39.4K	0.01%	526

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

RBC Europe's CLB Position: Q4 2021 in Review

RBC Europe sold out of Core Laboratories (CLB) in Q4 2021, closing a stake of 12,481 shares — an estimated $346K sold.

RBC Europe first reported a position in CLB in Q3 2017 and held it in 17 quarters. The position peaked at $486K in Q2 2021. 173 funds tracked by Wall St. Rank hold CLB as of Q4 2021.

RBC Europe reported no remaining Core Laboratories position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 12,481 Core Laboratories shares in Q4 2021, an estimated $346K.
RBC Europe first reported a position in Core Laboratories in Q3 2017 and held it in 17 quarters.
RBC Europe's Core Laboratories position peaked at $486K in Q2 2021.
173 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.